163 related articles for article (PubMed ID: 17437019)
1. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Almond J; Ralston S
Br J Cancer; 2007 May; 96(9):1489; author reply 1490. PubMed ID: 17437019
[No Abstract] [Full Text] [Related]
2. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Ward SE; Kaltenthaler E; Cowan J; Marples M; Orr B; Seymour MT
Br J Cancer; 2006 Jul; 95(1):27-34. PubMed ID: 16804526
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
Prescrire Int; 2002 Apr; 11(58):44-7. PubMed ID: 11987311
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Chu E; Cartwright TH
J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
[No Abstract] [Full Text] [Related]
6. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Cassidy J; Schmoll HJ; Van Cutsem E
J Clin Oncol; 2008 May; 26(13):2226-7; author reply 2228. PubMed ID: 18445855
[No Abstract] [Full Text] [Related]
7. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
Comella P; Casaretti R; Sandomenico C; Avallone A; Franco L
Drugs; 2008; 68(7):949-61. PubMed ID: 18457461
[TBL] [Abstract][Full Text] [Related]
8. Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Adimi P; Hansen F; Kjaer M; Aabo K; Keldsen N; Pfeiffer P; Sandberg E; Jakobsen A
Acta Oncol; 2002; 41(2):202-3. PubMed ID: 12102169
[No Abstract] [Full Text] [Related]
9. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
[TBL] [Abstract][Full Text] [Related]
10. [Colorectal cancer: irinotecan in combination with newer drugs].
Falcone A
Tumori; 2001; 87(6):A31-3. PubMed ID: 11995705
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Wu B; Li T; Cai J; Xu Y; Zhao G
BMC Cancer; 2014 Dec; 14():984. PubMed ID: 25526802
[TBL] [Abstract][Full Text] [Related]
12. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Nakayama T; Noguchi S
Oncologist; 2010; 15(1):26-36. PubMed ID: 20080863
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Best JH; Garrison LP
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):103-14. PubMed ID: 20384557
[TBL] [Abstract][Full Text] [Related]
16. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
17. [Oral fluoropyrimidines in the treatment of colorectal carcinoma].
Porschen R
Dtsch Med Wochenschr; 2003 Jun; 128 Suppl 2():S121-3. PubMed ID: 12817344
[No Abstract] [Full Text] [Related]
18. Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
Hochster HS
Clin Adv Hematol Oncol; 2005 May; 3(5):405-6. PubMed ID: 16167014
[No Abstract] [Full Text] [Related]
19. Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
Hsu TC; Wang CC
J Comp Eff Res; 2019 Jan; 8(2):73-79. PubMed ID: 30560687
[TBL] [Abstract][Full Text] [Related]
20. [Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Croockewit AJ; de Boer JE; van Loenhout JW; Koopmans PP
Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1117-20. PubMed ID: 12092301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
